ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 5

Antiphospholipid-Associated Nephropathy Is a Risk for Developing Arterial Thromboses in Patients with Systemic Lupus Erythematosus

Tomoko Fukui, Shinsuke Yasuda, Toshiyuki Watanabe, Kazumasa Ohmura, Sanae Shimamura, Ikuma Nakagawa, Atsushi Noguchi, Haruki Shida, Yuka Shimizu, Michihito Kono, Takashi Kurita, Kenji Oku, Toshiyuki Bohgaki, Olga Amengual, Tetsuya Horita and Tatsuya Atsumi, Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Antiphospholipid antibodies, antiphospholipid syndrome, lupus nephritis and thrombosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Antiphospholipid Syndrome

Session Type: Abstract Submissions (ACR)

Background/Purpose: Antiphospholipid-associated nephropathy (APLN) is characterized by coexistence of antiphospholipid antibodies (aPLs) and renal small-vessel vasculopathy/chronic renal ischemia. Consequences of APLN to thrombosis have yet to be known. We aimed in this study to clarify the characteristics and thrombotic risk of APLN in patients with lupus nephritis (LN).
Methods: Patients with LN proven by renal biopsy from January 2000 to February 2014 were included. A total of 90 patients were histologically diagnosed as having LN according to the ISN/RPS classification. APLN was diagnosed when both aPLs and at least one of the following pathological features were
present, thrombotic microangiopathy (TMA), fibrous intimal hyperplasia (FIH), fibrocellular arterial occlusion (FAO), focal cortical atrophy (FCA) or tubular thyroidization (TUB) according to the criteria (Miyakis S et al. J Thromb Haemost 2006). Patients with antiphospholipid syndrome were excluded. aPLs including lupus anticoagulant, IgG/M anticardiolipin antibody, IgG/M anti-b2-glycoprotein I antibody and IgG/M phosphatidylserine dependent antiprothrombin antibody were measured. Clinical features of APLN patients were retrospectively analyzed. Development of arterial thrombosis was retrospectively observed. Log-rank test was introduced for the comparison between those with APLN and  without.
Results: Among 90 patients with biopsy-proven LN, 21 were excluded (10 with APS, 5 without tests for aPLs and 6 for other reasons) and the rest 69 patients were recruited in the study. The median age and mean disease duration was 33 years old and 4.8 years, respectively. Twelve patients (17.4%) were diagnosed as APLN (9 FCA, 5 FIH, 1 FAO and 1 TUB) and 10 as APLN-like disease without aPL and with pathological features. Patients with APLN had higher frequency of hypertension (p-value by chi-square test =0.002). APLN patients more frequently developed arterial thrombosis during the median observation period of 53 months (p-value by log-rank test = 0.018) compared with patients without APLN.
Among patients positive for aPLs,patients with APLN had higher frequency of hypertension (p-value < 0.001) and developing arterial thrombosis (p-value=0.046) than patients without APLN. (Figure)

Conclusion: APLN was found in 17% of LN and associated with hypertension. APLN with LN is a possible risk for developing arterial thrombosis, although prospective study in a larger cohort would be necessary.


Disclosure:

T. Fukui,
None;

S. Yasuda,
None;

T. Watanabe,
None;

K. Ohmura,
None;

S. Shimamura,
None;

I. Nakagawa,
None;

A. Noguchi,
None;

H. Shida,
None;

Y. Shimizu,
None;

M. Kono,
None;

T. Kurita,
None;

K. Oku,
None;

T. Bohgaki,
None;

O. Amengual,
None;

T. Horita,
None;

T. Atsumi,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/antiphospholipid-associated-nephropathy-is-a-risk-for-developing-arterial-thromboses-in-patients-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology